ReviewDrug design, development and therapy2021
Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis.
Review in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Effectiveness of low-level laser therapy in reducing pain score and healing time of recurrent aphthous stomatitis: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- A Novel Oral Film Formulation for Jujuboside: Response Surface Optimization of Preparation Parameters and Performance Evaluation.Foods (Basel, Switzerland) · 2026Article
- Advances in the treatment of recurrent aphthous stomatitis: from synthetic and natural drugs to novel drug delivery systems.Frontiers in pharmacology · 2026Review
- Herbal Mucoadhesive Gels for Canker Sores: Analysis of Physicochemical Properties, Efficacy, and Safety.Combinatorial chemistry & high throughput screening · 2026Article
- The study of the therapeutic effect and preliminary mechanism of EGCG on recurrent aphthous ulcer.Scientific reports · 2025Article
- Oral Gel Formulation ofPharmaceutics · 2025Article
- The Efficacy of Rosehip Oil Emulsion as a Pro-Healing Herbal Medicine for the Treatment of Induced Mucosal Ulcer (Cell Culture and Experimental Study).Oral health & preventive dentistry · 2025Article
- Gels as Promising Delivery Systems: Physicochemical Property Characterization and Recent Applications.Pharmaceutics · 2025Review
- Preparing and Characterizing of Xyloglucan Films Containing Tea Extract for Oral Mucositis.ACS omega · 2025Article
- Recombinant Humanized Collagen Type XVII Promotes Oral Ulcer Healing via Anti-Inflammation and Accelerate Tissue Healing.Journal of inflammation research · 2024Article
- α-Mangostin hydrogel film with chitosan alginate base for recurrent aphthous stomatitis (RAS) treatment: study protocol for double-blind randomized controlled trial.Frontiers in pharmacology · 2024Article
- Natural and Synthetic Drugs Approached for the Treatment of Recurrent Aphthous Stomatitis Over the Last Decade.Drug design, development and therapy · 2024Review
- Article
- Oral Mucosa Models to Evaluate Drug Permeability.Pharmaceutics · 2023Review
- Mucoadhesive polymers in substance-based medical devices: functional ingredients or what else?Frontiers in drug safety and regulation · 2023Review
- Article
- A Fresh Look at Mouthwashes-What Is Inside and What Is It For?International journal of environmental research and public health · 2022Article
- The applications of polysaccharides in dentistry.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent aphthous stomatitis (RAS) is a disease marked by painful oral lesions on the buccal and labial mucosa or tongue. Drug delivery systems (DDS) for RAS include topical forms that manage wound healing, cover the ulcer, and relieve the associated pain. DDS targeting the oral mucosa face a major challenge, especially the short residence times in the mouth due to the effect of "saliva wash-out", which continually removes the drug. The objective of this review is to study the development of preparation forms and delivery systems of various types and preparations that have been used for RAS management from 1965 until February 2020. There are 20 types of DDS for RAS which were discussed in 62 articles. The preparations were classified into 4 preparation forms: liquid, semi-solid, solid, and miscellaneous. In addition, the ultimate DDS for RAS preparations is the semi-solid forms (41.94%), which include 5 types of DDS are gel, paste, patch, cream, and ointment. This preparation was developed into new preparation form (11.29%), such as adhesive alginates, dentifrice, OraDisc, membranes, bioresorbable plates, pellicles, and gelosomes. Generally, the mucosal drug delivery system is the method of choice in RAS treatment because the ulcer is commonly located in the oral mucosa. In conclusion, these preparations are designed to improve drug delivery and drug activity for the treatment of RAS ulcers. Moreover, almost all of these DDS are topical preparations that use various types of mucoadhesive polymers to increase both residence time in the oral mucosa and pain relief in RAS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.